Table 5 Outcomes for all the group and according the timing of alloSCT (front-line, second-line treatment, or progressive disease)
Number | Overall survival, % (95% CI) | Cumulative incidence of relapse, % (95% CI) | TRM, % (95% CI) | GRFS, % (95% CI) | |||
|---|---|---|---|---|---|---|---|
2-year OS | 4-year OS | At 2 years | 2-year TRM | 4-year TRM | 2-year GRFS | ||
All group | 285 | 65% (0.59–0.7) | 59% (0.53–0.65) | 19% (0.14–0.24) | 24% (0.3–0.19) | 28% (0.34–0.23) | 46% (0.4–0.52) |
Front-line alloSCT (CR1 + PR1) | 138 | 66% (0.58.0.74) | 63% (0.53–0.7) | 19% (0.12–0.25) | 23% (0.16–0.31) | 24% (0.17–0.32) | 48% (0.39–0.56) |
CR1 | 93 | 71% (0.6–0.79) | 62% (0.51–0.71) | 14% (0.13–0–51) | 26% (0.53–0.74) | 27% (0.38–0.19) | 48% (0.37–0.58) |
Second-line alloSCT (CR ≥ 2 or PR ≥ 2) | 116 | 66% (0.56–0.74) | 61% (0.51–0.7) | 17% (0.1–0.24) | 25% (0.18–0.35) | 30% (0.22–0.4) | 45% (0.36–0.54) |
Progressive disease | 31 | 55% (0.36–0.7) | 37% (0.2–0.54) | 32% (0.13–0.52) | 24% (0.46–0.12) | 40% (0.63–0.23) | 30% (0.19–0.56) |